WallStreetZenWallStreetZen

NASDAQ: XERS
Xeris Biopharma Holdings Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Xeris Biopharma Holdings revenue was $246.03M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q2 2025) ending on Jun 30, 2025 was $71.5M, up 19% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, XERS annual revenue was $203.1M, with 23.9% growth year-over-year.

XERS past revenue growth

How has XERS's revenue growth performed historically?

Company
35.62%
Industry
148.51%
Market
20.24%
XERS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
XERS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
XERS's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

XERS revenue history

Current Revenue
$246.0M
Current Earnings
-$32.0M
Current Profit Margin
-13%

Be the first to know when XERS announces revenue.

XERS Revenue History By Year

XERS Yearly RevenueXERS RevenueXERS ChangeXERS Revenue Growth
2024-12-31$203.07M$39.16M+23.89%
2023-12-31$163.91M$53.67M+48.68%
2022-12-31$110.25M$60.66M+122.32%
2021-12-31$49.59M$29.16M+142.67%
2020-12-31$20.44M$17.71M+650.73%
2019-12-31$2.72M$299.00k+12.34%
2018-12-31$2.42M$867.00k+55.72%
2017-12-31$1.56M$481.00k+44.74%
2016-12-31$1.08MN/AN/A

1 of 1

Xeris Biopharma Holdings Revenue FAQ

What was XERS's revenue last quarter?

On Invalid Date, Xeris Biopharma Holdings (NASDAQ: XERS) reported Q2 2025 revenue of $71.54 million up 48.84% year over year. In the same quarter last year, Xeris Biopharma Holdings's revenue was $48.07 million.

What was Xeris Biopharma Holdings's revenue in 2024?

Xeris Biopharma Holdings's annual revenue for the twelve months ending Dec 31, 2024 was $203.07 million, a 23.89% increase year over year.

How much does Xeris Biopharma Holdings make in a day?

Based on Xeris Biopharma Holdings annual revenue for the past five years, XERS makes an average of $299,866.85 per day.

What was Xeris Biopharma Holdings's annual revenue growth in the past year?

As of Q4 2025, Xeris Biopharma Holdings's revenue has grown 35.62% year over year. This is 112.89 percentage points lower than the US Biotechnology industry revenue growth rate of 148.51%. Xeris Biopharma Holdings's revenue in the past year totaled $246.03 million.

How much does Xeris Biopharma Holdings make in a year?

Xeris Biopharma Holdings's revenue by year for the past five years is:
  • Xeris Biopharma Holdings's revenue for the twelve months ending Dec 31, 2024 was $203.07 million, a 23.89% increase year over year.
  • Xeris Biopharma Holdings's annual revenue for Dec 31, 2023 was $163.91 million, a 48.68% increase from 2022.
  • Xeris Biopharma Holdings's annual revenue for 2022 was $110.25 million, a 122.32% increase from 2021.
  • Xeris Biopharma Holdings's annual revenue for 2021 was $49.59 million, a 142.67% increase from 2020.
  • Xeris Biopharma Holdings's annual revenue for 2020 was $20.44 million, a 650.73% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.